Skip to main content
. 2019 May 29;8:212581. doi: 10.7573/dic.212581

Table 3.

Proportion of patients who were reported to suffer kidney stone TEAEs in the pivotal studies of lesinurad.

XOI alone * Lesinurad 200 + XOI Lesinurad 400 + XOI
CLEAR 1 (allopurinol) 2.0% 1.0% 2.5%
CLEAR 2 (allopurinol) 0.5% 0% 3.0%
CRYSTAL (febuxostat) 3.7% 0.9% 1.8%

TEAEs, treatment-emergent adverse effects; XOI, xanthine oxidase inhibitor.